RESUMO
[This corrects the article DOI: 10.3389/fmicb.2022.1048457.].
RESUMO
Cervical cancer is a public health issue with high disease burden and mortality in Brazil. The objectives of the present study were, firstly, to analyze age, period, and cohort effects on cervical cancer mortality in women 20 years old or older from 1980 to 2019 in the North, South, and Southeast Regions of Brazil; and secondly, to evaluate whether the implementation of a national screening program and the expansion of access to public health services impacted the examined period and reduced the risk of death compared with previous years and among younger cohorts. The effects were estimated by applying Poisson regression models with estimable functions. The highest mortality rate per 100,000 women was found in Amazonas (24.13), and the lowest in São Paulo (10.56). A positive gradient was obtained for death rates as women's age increased. The states in the most developed regions (South and Southeast) showed a reduction in the risk of death in the period that followed the implementation of the screening program and in the cohort from the 1960s onwards. The North Region showed a decreased risk of death only in Amapá (2000-2004) and Tocantins (1995-2004; 2010-2019). The findings indicate that health inequities remain in Brazil and suggest that the health system has limitations in terms of decreasing mortality associated with this type of cancer in regions of lower socioeconomic development.
Assuntos
Neoplasias do Colo do Útero , Adulto , Brasil/epidemiologia , Efeito de Coortes , Estudos de Coortes , Feminino , Humanos , Programas de Rastreamento , Mortalidade , Neoplasias do Colo do Útero/epidemiologia , Adulto JovemRESUMO
Resumo Introdução Os medicamentos são a intervenção terapêutica mais utilizada e a mais custo efetiva para o tratamento de diversas patologias. A falta de acesso a medicamentos entre grupos com menores condições socioeconômicas representa uma iniquidade nos cuidados com a saúde. Nesse sentido, o fornecimento gratuito de medicamentos pelo setor público é essencial para a promoção da equidade. Objetivo Avaliar a mudança, no tempo, da prevalência de acesso gratuito, pela população adulta brasileira, a medicamentos prescritos no Sistema Único de Saúde (SUS) ao longo de 10 anos. Método Análise dos dados, por regressão logística, das Pesquisas Nacionais por Amostra de Domicílios (PNAD) realizadas no Brasil em 1998, 2003 e 2008. A variável de interesse foi o acesso gratuito a medicamentos prescritos. Resultados O acesso gratuito a medicamentos pelo Sistema Único de Saúde aumentou ao longo do tempo. Indivíduos com renda socioeconômica mais baixa tiveram maior chance de acesso a medicamentos e esse cenário se manteve constante ao longo dos anos avaliados. Conclusão Os achados revelam a importância do SUS como ferramenta efetiva para a promoção do acesso a medicamentos, especialmente para os indivíduos mais pobres. Entretanto, a redução da desigualdade no acesso a medicamentos permanece como desafio.
Abstract Background The medicines are the most used and most effective therapeutic intervention for the treatment of various pathologies. The lack of access to medicines among groups with lower socioeconomic conditions represents an inequity in health care. In this sense, the public supply of medicines is free of charge by the public sector to promote equity. Objective To evaluate the change, in time and prevalence of free access, by the Brazilian adult population, to medicines prescribed in the Unified Health System (SUS) over 10 years. Method Data came from the National Household Sample Surveys (PNAD) conducted in Brazil in 1998, 2003 and 2008. The dependent variable was free access to prescribed medicines. Results Free access to medicines in the SUS increased over time. Individuals with lower socioeconomic income had higher chance to access the medicines and this scenario remained constant over the years evaluated. Conclusion The findings reveal the importance of SUS as an effective tool for promoting access to medicines, especially for the poorest individuals. However, reducing inequality in access to medicines remains a challenge.
RESUMO
Background: Schistosomiasis is a parasitic disease associated with poverty. It is estimated that 7.1 million people are infected with Schistosoma mansoni in Latin America, with 95% of them living in Brazil. Accurate diagnosis and timely treatment are important measures to control and eliminate schistosomiasis, but diagnostic improvements are needed to detect infections, especially in areas of low endemicity. Methodology: This research aimed to evaluate the performance of 11 diagnostic tests using latent class analysis (LCA). A cross-sectional survey was undertaken in a low endemicity area of the municipality of Malacacheta, Minas Gerais, Brazil. Feces, urine, and blood samples were collected from 400 residents older than 6 years of age, who had not been treated with praziquantel in the 12 months previous to the collection of their samples. The collected samples were examined using parasitological (Helm Test® kit Kato-Katz), nucleic acid amplification tests -NAATs (PCR, qPCR and LAMP on urine; PCR-ELISA, qPCR and LAMP on stool), and immunological (POC-CCA, the commercial anti-Schistosoma mansoni IgG ELISA kit from Euroimmun, and two in-house ELISA assays using either the recombinant antigen PPE or the synthetic peptide Smp150390.1) tests. Results: The positivity rate of the 11 tests evaluated ranged from 5% (qPCR on urine) to 40.8% (commercial ELISA kit). The estimated prevalence of schistosomiasis was 12% (95% CI: 9-15%) according to the LCA. Among all tests assessed, the commercial ELISA kit had the highest estimated sensitivity (100%), while the Kato-Katz had the highest estimated specificity (99%). Based on the accuracy measures observed, we proposed three 2-step diagnostic approaches for the active search of infected people in endemic settings. The approaches proposed consist of combinations of commercial ELISA kit and NAATs tests performed on stool. All the approaches had higher sensitivity and specificity than the mean values observed for the 11 tests (70.4 and 89.5%, respectively). Conclusion: We showed that it is possible to achieve high specificity and sensitivity rates with lower costs by combining serological and NAATs tests, which would assist in the decision-making process for appropriate allocation of public funding aiming to achieve the WHO target of eliminating schistosomiasis as a public health problem by 2030.
RESUMO
BACKGROUND: In Brazil, case-fatality from visceral leishmaniasis (VL) is high and characterized by wide differences between the various political-economic units, the federated units (FUs). This study was designed to investigate the association between factors at the both FU and individual levels with the risk of dying from VL, after analysing the temporal trend and the spatial dependency for VL case-fatality. METHODOLOGY: The analysis was based on individual and aggregated data of the Reportable Disease Information System-SINAN (Brazilian Ministry of Health). The temporal and spatial distributions of the VL case-fatality between 2007 and 2017 (27 FUs as unit of analysis) were considered together with the individual characteristics and many other variables at the FU level (socioeconomic, demographic, access to health and epidemiological indicators) in a mixed effects models or multilevel modeling, assuming a binomial outcome distribution (death from VL). FINDINGS: A linear increasing temporal tendency (4%/year) for VL case-fatality was observed between 2007 and 2017. There was no similarity between the case-fatality rates of neighboring FUs (non-significant spatial term), although these rates were heterogeneous in this spatial scale of analysis. In addition to the known individual risk factors age, female gender, disease's severity, bacterial co-infection and disease duration, low level schooling and unavailability of emergency beds and health professionals (the last two only in univariate analysis) were identified as possibly related to VL death risk. Lower VL incidence was also associated to VL case-fatality, suggesting that unfamiliarity with the disease may delay appropriate medical management: VL patients with fatal outcome were notified and had VL treatment started 6 and 3 days later, respectively, in relation to VL cured patients. Access to garbage collection, marker of social and economic development, seems to be protective against the risk of dying from VL. Part of the observed VL case-fatality variability in Brazil could not be explained by the studied variables, suggesting that factors linked to the intra FU environment may be involved. CONCLUSIONS: This study aimed to identify epidemiological conditions and others related to access to the health system possibly linked to VL case-fatality, pointing out new prognostic determinants subject to intervention.
Assuntos
Leishmaniose Visceral/epidemiologia , Leishmaniose Visceral/mortalidade , Mortalidade , Brasil/epidemiologia , Feminino , Humanos , Leishmaniose Visceral/economia , Masculino , Modelos Biológicos , Vigilância da População , Fatores de Risco , População Rural , População Urbana , Adulto JovemRESUMO
INTRODUCTION: The objective of this study was to estimate the direct medical costs of the treatment for mucosal leishmaniasis (ML) using three therapeutic approaches in the Brazilian context. METHODS: We performed this economic assessment from the perspective of the Brazilian public healthcare system. The following therapeutic approaches were evaluated: meglumine antimoniate, liposomal amphotericin B, and miltefosine. Direct medical costs were estimated considering four treatment components: a) drug, b) combined medical products, c) procedures, and d) complementary tests. RESULTS: Treatment with meglumine antimoniate had the lowest average cost per patient (US$ 167.66), followed by miltefosine (US$ 259.92) in the outpatient treatment regimen. The average cost of treatment with liposomal amphotericin B was US$ 715.35 both in inpatient regimen. In all estimates, the drugs accounted for more than 60% of the total cost for each treatment approach. CONCLUSIONS: These results demonstrate the marked differences in costs between the therapeutic alternatives for ML. In addition to efficacy rates and costs related to adverse events, our data have the potential to support a complete cost-effectiveness study in the future. Complete analyses comparing costs and benefits for interventions will assist health managers in choosing drugs for ML treatment in Brazil as well as in establishing effective public health policies.
Assuntos
Antiprotozoários , Leishmaniose Mucocutânea , Antiprotozoários/uso terapêutico , Brasil , Análise Custo-Benefício , Humanos , Leishmaniose Mucocutânea/tratamento farmacológico , Antimoniato de Meglumina/uso terapêuticoRESUMO
Abstract INTRODUCTION: The objective of this study was to estimate the direct medical costs of the treatment for mucosal leishmaniasis (ML) using three therapeutic approaches in the Brazilian context. METHODS: We performed this economic assessment from the perspective of the Brazilian public healthcare system. The following therapeutic approaches were evaluated: meglumine antimoniate, liposomal amphotericin B, and miltefosine. Direct medical costs were estimated considering four treatment components: a) drug, b) combined medical products, c) procedures, and d) complementary tests. RESULTS: Treatment with meglumine antimoniate had the lowest average cost per patient (US$ 167.66), followed by miltefosine (US$ 259.92) in the outpatient treatment regimen. The average cost of treatment with liposomal amphotericin B was US$ 715.35 both in inpatient regimen. In all estimates, the drugs accounted for more than 60% of the total cost for each treatment approach. CONCLUSIONS: These results demonstrate the marked differences in costs between the therapeutic alternatives for ML. In addition to efficacy rates and costs related to adverse events, our data have the potential to support a complete cost-effectiveness study in the future. Complete analyses comparing costs and benefits for interventions will assist health managers in choosing drugs for ML treatment in Brazil as well as in establishing effective public health policies.
Assuntos
Humanos , Leishmaniose Mucocutânea/tratamento farmacológico , Antiprotozoários/uso terapêutico , Brasil , Análise Custo-Benefício , Antimoniato de Meglumina/uso terapêuticoRESUMO
Cutaneous leishmaniasis (CL) is a disease associated with low-income populations. Thus, in assessing the burden of this disease, it is important to include its economic impact on individuals. We aimed to evaluate CL economic impact on patients treated at a referral service in the State of Minas Gerais, Brazil. This is a cross-sectional study based on the analysis of interviews and medical records from which we assembled direct medical and non-medical costs related to CL, from a societal perspective. One hundred patients were included; 50% had a monthly per capita income of up to USD 259.60 and spent on average USD 187.32 with the disease, representing an average monthly impact of 22.5% (USD 133.80). The disease imposed direct medical costs, such as: private medical appointments, medications, medical exams, dressing material, and co-participation in health insurances. Direct non-medical costs were mainly related to patients' transportation to health centers (USD 4,911.00), but also included medically-necessary care, food, and domestic and business outsourcing services. Although the Brazilian public health system guarantees access to health care, CL still represents a substantial economic impact for patients. The main action to reduce the expenses with this disease is decentralizing services for CL diagnosis and therapeutic approach, as well as increasing their efficiency.
Assuntos
Custos de Cuidados de Saúde , Leishmaniose Cutânea , Adulto , Brasil/epidemiologia , Estudos Transversais , Humanos , Leishmaniose Cutânea/economia , Leishmaniose Cutânea/epidemiologia , Encaminhamento e ConsultaRESUMO
OBJECTIVE: To evaluate non-adherence to pharmacotherapy for chronic diseases and to investigate the existence of socioeconomic inequalities related to this outcome in Brazil. METHODS: This was a cross-sectional study based on data from the National Survey on Access, Use and Promotion of the Rational Use of Medicines (PNAUM). The study population corresponded to individuals aged 18 years or older with a medical diagnosis of at least one chronic disease and an indication for pharmacological treatment. The dependent variable was non-adherence to chronic disease pharmacotherapy measured by less than 80% adherence to drug therapy. Socioeconomic inequality related to non-adherence was assessed by absolute (SII) and relative (RII) inequality indices, calculated by logistic regression analyses. RESULTS: The prevalence of non-adherence to pharmacotherapy in Brazil was 20.2%, ranging from 17.0 to 27.8% between regions. Furthermore, this study revealed absolute and relative socioeconomic inequalities in non-adherence to pharmacotherapy of chronic diseases in Brazil (SII = -7.4; RII = 0.69) and the Northeast (SII = -14.0; RII = 0.59) and Center West (SII = -20.8; RII = 0.38) regions. The probability of non-adherence to pharmacotherapy in Brazil was higher among individuals with worse socioeconomic status. CONCLUSION: The findings of the present study indicate the need for the restructuring and strengthening of public policies aimed at reducing socioeconomic inequalities, in order to promote equity in adherence to the pharmacotherapy associated with chronic diseases.
Assuntos
Doença Crônica/tratamento farmacológico , Adesão à Medicação/estatística & dados numéricos , Adolescente , Adulto , Brasil , Estudos Transversais , Humanos , Fatores SocioeconômicosRESUMO
Cervical cancer (CC) is a public health problem with a high disease burden and mortality in developing countries. In Brazil, areas with low human development index have the highest incidence rates of Brazil and upward temporal trend for this disease. The Northeast region has the second highest incidence of cervical cancer (20.47 new cases / 100,000 women). In this region, the mortality rates are similar to rates in countries that do not have a health system with a universal access screening program, as in Brazil. Thus, this study aimed to analyze the effects of age, period and birth cohorts on mortality from cervical cancer in the Northeast region of Brazil. Estimable functions predicted the effects of age, period and birth cohort. The average mortality rate was 10.35 deaths per 100,000 women during the period analyzed (1980-2014). The highest mortality rate per 100,000 women was observed in Maranhão (24.39 deaths), and the lowest mortality rate was observed in Bahia (11.24 deaths). According to the period effects, only the state of Rio Grande do Norte showed a reduction in mortality risk in the five years of the 2000s. There was a reduction in mortality risk for birth cohorts of women after the 1950s, except in Maranhão State, which showed an increasing trend in mortality risk for younger generations. We found that the high rates of cervical cancer mortality in the states of northeastern Brazil remain constant over time. Even after an increase in access to health services in the 2000s, associated with increased access to the cancer care network, which includes early detection (Pap Test), cervical cancer treatment and palliative care. However, it is important to note that the decreased risk of death and the mortality rates from CC among women born after the 1960s may be correlated with increased screening coverage, as well as increased access to health services for cancer treatment observed in younger women.
Assuntos
Neoplasias do Colo do Útero/epidemiologia , Neoplasias do Colo do Útero/mortalidade , Adulto , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Brasil/epidemiologia , Estudos de Coortes , Detecção Precoce de Câncer , Feminino , Acessibilidade aos Serviços de Saúde , Humanos , Incidência , Programas de Rastreamento/economia , Pessoa de Meia-Idade , Mortalidade , Teste de Papanicolaou , Adulto JovemRESUMO
Cutaneous leishmaniasis (CL) is a disease associated with low-income populations. Thus, in assessing the burden of this disease, it is important to include its economic impact on individuals. We aimed to evaluate CL economic impact on patients treated at a referral service in the State of Minas Gerais, Brazil. This is a cross-sectional study based on the analysis of interviews and medical records from which we assembled direct medical and non-medical costs related to CL, from a societal perspective. One hundred patients were included; 50% had a monthly per capita income of up to USD 259.60 and spent on average USD 187.32 with the disease, representing an average monthly impact of 22.5% (USD 133.80). The disease imposed direct medical costs, such as: private medical appointments, medications, medical exams, dressing material, and co-participation in health insurances. Direct non-medical costs were mainly related to patients' transportation to health centers (USD 4,911.00), but also included medically-necessary care, food, and domestic and business outsourcing services. Although the Brazilian public health system guarantees access to health care, CL still represents a substantial economic impact for patients. The main action to reduce the expenses with this disease is decentralizing services for CL diagnosis and therapeutic approach, as well as increasing their efficiency.
A leishmaniose cutânea (LC) é uma doença associada a populações de baixa renda. Portanto, a inclusão do impacto financeiro sobre os pacientes é muito importante para avaliar a carga dessa doença. Tivemos como objetivo avaliar o impacto econômico da LC em pacientes afetados pela doença e tratados em um centro de referência para LC no Estado de Minas Gerais, Brasil. Foi um estudo transversal com base em análise de entrevistas e prontuários médicos para compilação dos gastos médicos e não médicos diretos relacionados à LC, desde uma perspectiva societal. Foram incluídos cem pacientes; 50% tinham renda mensal per capita de até USD 259,60. O gasto médio na doença foi de USD 187,32, o que representa um impacto mensal médio de 22,5% (USD 133,80). A doença impôs custos médicos diretos, como o pagamento por consultas médicas particulares, exames médicos, material para curativos e co-participação em seguro de saúde. Os custos não médicos diretos estiveram relacionados ao transporte dos pacientes até os centros de saúde, cuidados adicionais, alimentação e contratos com serviços terceirizados para atividades domésticas e laborais. O transporte dos pacientes para as consultas médicas representava a principal parcela dos gastos (USD 4.911,00). Embora o acesso à assistência à saúde seja um direito garantido pelo Sistema Único de Saúde, a LC ainda gera um impacto financeiro substancial para os pacientes. A descentralização dos serviços diagnósticos e terapêuticos para LC e o aumento de sua eficiência são as principais medidas que podem reduzir os gastos com essa doença.
La leishmaniosis cutánea (LC) es una enfermedad asociada a poblaciones con ingresos bajos. Por ello, incluir el impacto financiero para las personas es muy importante a la hora de evaluar la carga de esta enfermedad. Nuestro objetivo fue evaluar el impacto económico de la LC, de pacientes afectados por esta enfermedad, que fueron tratados por un servicio de referencia para el tratamiento de la LC en el Estado de Minas Gerais, Brasil. Este estudio transversal basado en entrevistas y análisis de registros médicos para la recopilación de gastos médicos y no-médicos directos, relacionados con la LC desde una a perspectiva social. Se incluyeron a cien pacientes; el 50% contaba con ingresos mensuales per cápita de hasta USD 259,60 y gastaban un promedio de USD 187,32 en la enfermedad, representando un impacto promedio mensual de 22,5% (USD 133,80). La enfermedad supuso costes médicos directos, como el pago de citas médicas privadas, medicamentos, exámenes médicos, material para vendajes, y coparticipación en seguros médicos. Los costes directos no-médicos estaban relacionados con el transporte de los pacientes a los centros de salud, el cuidado necesario, comida, y contratos con servicios externalizados para actividades domésticas y laborales. El transporte de los pacientes para citas médicas representó la principal razón para los gastos (USD 4.911,00). A pesar de que el acceso a los cuidados de salud es un derecho garantizado por el sistema de salud público brasileño, la LC todavía supone un impacto financiero importante para los pacientes. La descentralización de los servicios para el diagnóstico de LC, la aproximación terapéutica, y el incremento de su eficiencia, son las acciones con principal potencial para reducir los gastos financieros de esta enfermedad.
Assuntos
Humanos , Adulto , Leishmaniose Cutânea/economia , Leishmaniose Cutânea/epidemiologia , Custos de Cuidados de Saúde , Encaminhamento e Consulta , Brasil/epidemiologia , Estudos TransversaisRESUMO
RESUMO: Objetivos: Avaliar a não adesão à farmacoterapia de doenças crônicas e investigar a existência de desigualdades socioeconômicas relacionadas a esse desfecho no Brasil. Métodos: Estudo realizado com base em dados da Pesquisa Nacional sobre Acesso, Utilização e Promoção do Uso Racional de Medicamentos (PNAUM), de 2014. A população de estudo correspondeu a indivíduos com 18 anos ou mais, com diagnóstico médico de pelo menos uma doença crônica e com indicação de tratamento farmacológico. A variável dependente foi a não adesão à farmacoterapia de doenças crônicas, mensurada pela adesão menor que 80% à terapia medicamentosa. Avaliou-se a desigualdade socioeconômica relacionada a não adesão pelos índices absoluto (SII) e relativo (RII) de desigualdade, calculados por análise de regressão logística. Resultados: A prevalência de não adesão à farmacoterapia no Brasil foi de 20,2%, variando de 17 a 27,8% entre as regiões. Além disso, esse estudo revelou desigualdades socioeconômicas absoluta e relativa na não adesão à farmacoterapia de doenças crônicas no Brasil (SII = -7,4; RII = 0,69) e nas regiões Nordeste (SII = -14; RII = 0,59) e Centro-Oeste (SII = -20,8; RII = 0,38). A probabilidade de não adesão à farmacoterapia, no Brasil, é maior entre os indivíduos de pior condição socioeconômica. Conclusão: Os achados do presente estudo apontam a necessidade de reestruturação e fortalecimento das políticas públicas voltadas à redução das desigualdades socioeconômicas em prol da promoção da equidade na adesão à farmacoterapia de doenças crônicas.
ABSTRACT: Objective: To evaluate non-adherence to pharmacotherapy for chronic diseases and to investigate the existence of socioeconomic inequalities related to this outcome in Brazil. Methods: This was a cross-sectional study based on data from the National Survey on Access, Use and Promotion of the Rational Use of Medicines (PNAUM). The study population corresponded to individuals aged 18 years or older with a medical diagnosis of at least one chronic disease and an indication for pharmacological treatment. The dependent variable was non-adherence to chronic disease pharmacotherapy measured by less than 80% adherence to drug therapy. Socioeconomic inequality related to non-adherence was assessed by absolute (SII) and relative (RII) inequality indices, calculated by logistic regression analyses. Results: The prevalence of non-adherence to pharmacotherapy in Brazil was 20.2%, ranging from 17.0 to 27.8% between regions. Furthermore, this study revealed absolute and relative socioeconomic inequalities in non-adherence to pharmacotherapy of chronic diseases in Brazil (SII = -7.4; RII = 0.69) and the Northeast (SII = -14.0; RII = 0.59) and Center West (SII = -20.8; RII = 0.38) regions. The probability of non-adherence to pharmacotherapy in Brazil was higher among individuals with worse socioeconomic status. Conclusion: The findings of the present study indicate the need for the restructuring and strengthening of public policies aimed at reducing socioeconomic inequalities, in order to promote equity in adherence to the pharmacotherapy associated with chronic diseases.
Assuntos
Humanos , Adolescente , Adulto , Doença Crônica/tratamento farmacológico , Adesão à Medicação/estatística & dados numéricos , Fatores Socioeconômicos , Brasil , Estudos TransversaisRESUMO
BACKGROUND: Until now, few studies have evaluated the effect of cutaneous leishmaniasis (CL) on patients' quality of life, and none have used a specific instrument to measure this effect. The objective of this study was to identify factors that may be associated with the high impact of CL and to assess patients' satisfaction with treatment and health services by utilizing a disease-specific questionnaire. METHODOLOGY: Between December 2015 and May 2017, 100 patients with localized cutaneous leishmaniasis were interviewed at a leishmaniasis referral center in Brazil. Data were collected by two questionnaires. One questionnaire compiled the sociodemographic, economic, and clinical information related to the disease. The second questionnaire was the Cutaneous Leishmaniasis Impact Questionnaire (CLIQ), which consisted of two subscales that measured 1) the general impact of CL and 2) patients' perceptions of treatment and health services. The median scores from each of these two subscales were used to dichotomize the dependent variables. Risk factors for the high impact of CL and for low patient satisfaction with treatment and health services were analyzed with a logistic regression analysis. RESULTS: The chance of higher impact of CL was increased in patients with the presence of comorbidities (OR: 3.9; CI 1.25-12.36), in those with absences from work (OR: 12.0; CI 3.78-42.55), in those who relied on public transportation by a municipal bus (OR: 5.8; CI 1.27-26.77), and in those who had illness-related expenses greater than U$137 (OR: 3.5; CI 1.17-10.24). The chance of patient dissatisfaction with treatment and health services increased with higher education (OR: 5.0; CI 1.19-21.03) and with illness-related expenses exceeding U$137 (OR: 4.64; CI 1.49-14.48). Once the sample was non-probabilistic, findings are not representative of CL patients in general. CONCLUSIONS: CL and its treatment have a negative impact on patients' quality of life. Considering these effects during public health planning may help patients to confront the disease.
Assuntos
Leishmaniose Cutânea/psicologia , Satisfação do Paciente , Adulto , Idoso , Idoso de 80 Anos ou mais , Brasil , Efeitos Psicossociais da Doença , Estudos Transversais , Atenção à Saúde , Feminino , Humanos , Entrevistas como Assunto , Leishmaniose Cutânea/tratamento farmacológico , Leishmaniose Cutânea/economia , Modelos Logísticos , Masculino , Pessoa de Meia-Idade , Qualidade de Vida , Inquéritos e Questionários , Adulto JovemRESUMO
OBJECTIVE: To estimate the prevalence and check the factors associated with access to prescribed medicine by the Brazilian adult population; and to describe the distribution of the presence of monetary expenditure for the purchase, source of medicines, and the reasons for non-access. METHODS: Based on a cross-sectional design, from the 2013 National Health Research data, we analyzed a representative sample of the population that comprised adults with prescriptions written by a health professional, in the two weeks prior to the survey. The dependent variable was the access to prescribed medicines (full access, partial access, no access). Data were analyzed using the multinomial logistic regression considering total access as the reference category. RESULTS: The results showed high prevalence of full access to prescribed medicine in Brazil (83.0%; 95%CI 81.3 - 84.6). Most of the individuals had monetary expenditure on the purchase of medicines (63.9%), and the main reasons for no access were the lack of medicine in the public health service (57.6%) and having no money (11.9%). We found higher chances of partial access among individuals attending the public service (OR = 2.5; 95%CI 1.58 - 3.97). Greater chance of no access was associated with non-white skin color (OR = 1.43; 95%CI 1.03 - 1.99). CONCLUSION: The results revealed significant inequity in access to medicine, emphasizing the need to strengthen the Unified Health System for the free supply of medicines in order to reduce inequalities.
Assuntos
Acessibilidade aos Serviços de Saúde/estatística & dados numéricos , Medicamentos sob Prescrição , Adolescente , Adulto , Brasil , Estudos Transversais , Feminino , Gastos em Saúde , Humanos , Masculino , Pessoa de Meia-Idade , Medicamentos sob Prescrição/economia , Adulto JovemRESUMO
The objective of this study was to analyze the effect of age-period and cohort (APC) of birth on mortality for acute myocardial infarction in Brazil and its geographic regions, according to sex in the period from 1980 to 2009. The data was extracted from the Mortality Information System and was corrected and adjusted by means of proportional redistribution of records with sex and age ignored, ill-defined causes, and corrections were made based on the death sub-register. The APC was calculated using the Poisson regression model with estimable functions. The APC analysis on both sexes and in all regions of the country showed gradual reductions in the risk of death in birth cohorts from the decade of the 1940s, except in the Northeast. In this region, there have been progressive increases in the risk of death from the late 1940s for both sexes. This was up until the 1950s for men and the 1960s for women. It was concluded that the observed differences in the risk of death in Brazilian regions is the result of socio-economic inequalities and poor access to health services within the Brazilian territory, favoring early mortality for this cause especially in poorer areas.
Objetivou-se analisar o efeito da idade-período e coorte (APC) de nascimento na mortalidade por infarto agudo do miocárdio no Brasil e regiões geográficas, segundo sexo, no período de 1980 a 2009. Os dados foram extraídos do Sistema de Informação Sobre Mortalidade e foram corrigidos e ajustados, por meio da redistribuição proporcional dos registros com sexo e idade ignorados, causas mal definidas, e também se realizou a correção do sub-registro de morte. O APC foi calculado pelo modelo de regressão de Poisson, utilizando funções estimáveis. A análise APC nos dois sexos e em todas as regiões do país evidenciou progressiva redução no risco de morte nas coortes de nascimento a partir da década de 1940, exceto na região nordeste. Nessa região, verificou-se aumento progressivo do risco de morte a partir da década de 1940 para ambos os sexos, até a década de 1950 para os homens e a década de 1960 para as mulheres. Concluiu-se que as diferenças observadas no risco de morte nas regiões brasileiras é fruto das desigualdades socioeconômicas e de acesso aos serviços de saúde existente no território brasileiro, favorecendo a mortalidade precoce por essa causa sobretudo em localidades mais pobres.
Assuntos
Acessibilidade aos Serviços de Saúde , Disparidades nos Níveis de Saúde , Infarto do Miocárdio/mortalidade , Adulto , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Brasil/epidemiologia , Estudos de Coortes , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Infarto do Miocárdio/epidemiologia , Distribuição de Poisson , Fatores Sexuais , Fatores Socioeconômicos , Adulto JovemRESUMO
Resumo Objetivou-se analisar o efeito da idade-período e coorte (APC) de nascimento na mortalidade por infarto agudo do miocárdio no Brasil e regiões geográficas, segundo sexo, no período de 1980 a 2009. Os dados foram extraídos do Sistema de Informação Sobre Mortalidade e foram corrigidos e ajustados, por meio da redistribuição proporcional dos registros com sexo e idade ignorados, causas mal definidas, e também se realizou a correção do sub-registro de morte. O APC foi calculado pelo modelo de regressão de Poisson, utilizando funções estimáveis. A análise APC nos dois sexos e em todas as regiões do país evidenciou progressiva redução no risco de morte nas coortes de nascimento a partir da década de 1940, exceto na região nordeste. Nessa região, verificou-se aumento progressivo do risco de morte a partir da década de 1940 para ambos os sexos, até a década de 1950 para os homens e a década de 1960 para as mulheres. Concluiu-se que as diferenças observadas no risco de morte nas regiões brasileiras é fruto das desigualdades socioeconômicas e de acesso aos serviços de saúde existente no território brasileiro, favorecendo a mortalidade precoce por essa causa sobretudo em localidades mais pobres.
Abstract The objective of this study was to analyze the effect of age-period and cohort (APC) of birth on mortality for acute myocardial infarction in Brazil and its geographic regions, according to sex in the period from 1980 to 2009. The data was extracted from the Mortality Information System and was corrected and adjusted by means of proportional redistribution of records with sex and age ignored, ill-defined causes, and corrections were made based on the death sub-register. The APC was calculated using the Poisson regression model with estimable functions. The APC analysis on both sexes and in all regions of the country showed gradual reductions in the risk of death in birth cohorts from the decade of the 1940s, except in the Northeast. In this region, there have been progressive increases in the risk of death from the late 1940s for both sexes. This was up until the 1950s for men and the 1960s for women. It was concluded that the observed differences in the risk of death in Brazilian regions is the result of socio-economic inequalities and poor access to health services within the Brazilian territory, favoring early mortality for this cause especially in poorer areas.
Assuntos
Humanos , Masculino , Feminino , Adulto , Idoso , Idoso de 80 Anos ou mais , Adulto Jovem , Disparidades nos Níveis de Saúde , Acessibilidade aos Serviços de Saúde , Infarto do Miocárdio/mortalidade , Fatores Socioeconômicos , Brasil/epidemiologia , Distribuição de Poisson , Fatores Sexuais , Estudos de Coortes , Fatores Etários , Pessoa de Meia-Idade , Infarto do Miocárdio/epidemiologiaRESUMO
The main objective of the study was to analyze the effect of age, period and birth cohort on esophageal cancer mortality in Brazil and its geographic regions, per sex. An ecological study is presented herein, which evaluated the deaths by esophageal cancer and the distribution, per geographic region. Poisson Regression was utilized to calculate the effects of age, period and birth cohort, and projections were made with the statistical software R, using the age-period-cohort model. Projection of data covered the period 2015-2029. Regarding the geographic regions of Brazil, a decrease was verified, throughout time, for the mortality rates of the South and Southeast regions, for men and women. For the North, Northeast and Midwest regions, an increase was evidenced in mortality rates, mainly for men, after the 2000's. Regarding the projections, a progressive increase of mortality rates was verified for the Northeast and North regions. Divergences evidenced for observed and projected esophageal cancer mortality rates revealed inequalities among the geographic regions of Brazil.
Assuntos
Neoplasias Esofágicas/mortalidade , Modelos Biológicos , Adolescente , Adulto , Fatores Etários , Idoso , Idoso de 80 Anos ou mais , Brasil/epidemiologia , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Recém-Nascido , Masculino , Pessoa de Meia-Idade , Mortalidade , Fatores SocioeconômicosRESUMO
RESUMO: Objetivo: Estimar a prevalência e verificar os fatores associados ao acesso a medicamentos prescritos, pela população adulta brasileira, e descrever as distribuições de dispêndio monetário para acesso aos fármacos, fonte de obtenção e motivos para o não acesso. Métodos: Com base em um delineamento transversal, a partir dos dados da Pesquisa Nacional de Saúde de 2013, analisou-se uma amostra composta por indivíduos adultos que tiveram medicamentos prescritos por profissional de saúde, nas duas semanas anteriores à realização da pesquisa. A variável dependente foi o acesso a medicamentos prescritos (total, parcial, nulo). Os dados foram analisados por meio de regressão logística multinomial, considerando-se o acesso total como categoria de referência. Resultados: Os resultados mostraram alta prevalência de acesso total a medicamentos prescritos no Brasil (83,0%; IC95% 81,3 - 84,6). A maioria dos indivíduos teve dispêndio monetário com a obtenção dos fármacos (63,9%), sendo que os principais motivos para o não acesso foram a ausência do medicamento no serviço público de saúde (57,6%) e falta de dinheiro (11,9%). Foram observadas maiores chances de acesso parcial para os indivíduos atendidos no serviço público (OR = 2,5; IC95% 1,58 - 3,97). Maior chance de acesso nulo foi associada à cor de pele não branca (OR = 1,43; IC95% 1,03 - 1,99). Conclusão: Os resultados revelaram iniquidade no acesso a medicamentos, reforçando a necessidade de fortalecimento do Sistema Único de Saúde para o fornecimento gratuito de fármacos, de modo a reduzir as desigualdades.
ABSTRACT: Objective: To estimate the prevalence and check the factors associated with access to prescribed medicine by the Brazilian adult population; and to describe the distribution of the presence of monetary expenditure for the purchase, source of medicines, and the reasons for non-access. Methods: Based on a cross-sectional design, from the 2013 National Health Research data, we analyzed a representative sample of the population that comprised adults with prescriptions written by a health professional, in the two weeks prior to the survey. The dependent variable was the access to prescribed medicines (full access, partial access, no access). Data were analyzed using the multinomial logistic regression considering total access as the reference category. Results: The results showed high prevalence of full access to prescribed medicine in Brazil (83.0%; 95%CI 81.3 - 84.6). Most of the individuals had monetary expenditure on the purchase of medicines (63.9%), and the main reasons for no access were the lack of medicine in the public health service (57.6%) and having no money (11.9%). We found higher chances of partial access among individuals attending the public service (OR = 2.5; 95%CI 1.58 - 3.97). Greater chance of no access was associated with non-white skin color (OR = 1.43; 95%CI 1.03 - 1.99). Conclusion: The results revealed significant inequity in access to medicine, emphasizing the need to strengthen the Unified Health System for the free supply of medicines in order to reduce inequalities.
Assuntos
Humanos , Masculino , Feminino , Adolescente , Adulto , Adulto Jovem , Medicamentos sob Prescrição/economia , Acessibilidade aos Serviços de Saúde/estatística & dados numéricos , Brasil , Estudos Transversais , Gastos em Saúde , Pessoa de Meia-IdadeRESUMO
Passive surveillance of infectious diseases with a high percentage of asymptomatic cases or long incubation periods, such as acquired immunodeficiency syndrome (AIDS), does not reflect the current transmission dynamics. Thus, a multi-strategic surveillance, such as the human immunodeficiency virus (HIV) sentinel surveillance proposed by the World Health Organization (WHO), is necessary. The Brazilian HIV sentinel surveillance was started in May 1992 with this purpose. The objectives of this study were to evaluate the feasibility and costs of HIV and hepatitis C virus (HCV) surveillance using dried blood spots (DBS) collected for neonatal screening of metabolic diseases in the state of Minas Gerais, Brazil. This was accomplished through the comparison of HIV and HCV seroprevalence with previous Brazilian studies. From December 2001 to June 2002, 24,905 newborns were tested for HIV and 4211 for HCV. HIV seroprevalence was 0.25% and the 95% confidence interval (CI) was 0.18, 0.31%; and HCV seroprevalence was 0.71% and the 95% CI was 0.46, 0.97%. These numbers are similar to previous Brazilian studies. Cost in this study was approximately USD 3.10 per sample, which was roughly one third of the cost of the same exam at the Brazilian HIV sentinel surveillance. We conclude that it is possible and more cost-effective to use DBS for infectious diseases surveillance, albeit it is still necessary to compare these results with the usual sentinel methodology in a concomitant trial.
Assuntos
Coleta de Amostras Sanguíneas/métodos , Infecções por HIV/diagnóstico , Hepatite C/diagnóstico , Triagem Neonatal/métodos , Vigilância de Evento Sentinela , Brasil/epidemiologia , Estudos de Viabilidade , Infecções por HIV/epidemiologia , Custos de Cuidados de Saúde , Hepatite C/epidemiologia , Humanos , Recém-Nascido , Triagem Neonatal/economia , Fatores de Risco , Estudos SoroepidemiológicosRESUMO
Passive surveillance of infectious diseases with a high percentage of asymptomatic cases or long incubation periods, such as acquired immunodeficiency syndrome (AIDS), does not reflect the current transmission dynamics. Thus, a multi-strategic surveillance, such as the human immunodeficiency virus (HIV) sentinel surveillance proposed by the World Health Organization (WHO), is necessary. The Brazilian HIV sentinel surveillance was started in May 1992 with this purpose. The objectives of this study were to evaluate the feasibility and costs of HIV and hepatitis C virus (HCV) surveillance using dried blood spots (DBS) collected for neonatal screening of metabolic diseases in the state of Minas Gerais, Brazil. This was accomplished through the comparison of HIV and HCV seroprevalence with previous Brazilian studies. From December 2001 to June 2002, 24,905 newborns were tested for HIV and 4211 for HCV. HIV seroprevalence was 0.25 percent and the 95 percent confidence interval (CI) was 0.18, 0.31 percent; and HCV seroprevalence was 0.71 percent and the 95 percent CI was 0.46, 0.97 percent. These numbers are similar to previous Brazilian studies. Cost in this study was approximately US$ 3.10 per sample, which was roughly one third of the cost of the same exam at the Brazilian HIV sentinel surveillance. We conclude that it is possible and more cost-effective to use DBS for infectious diseases surveillance, albeit it is still necessary to compare these results with the usual sentinel methodology in a concomitant trial.